Cevimeline

Systematic (IUPAC) name
2-methyspiro (1,3- oxathiolane- 5,3) quinuclidine
Clinical data
Trade names	Evoxac
AHFS/Drugs.com	monograph
MedlinePlus	a608025
Pregnancy cat.	C
Legal status	Rx only
Routes	Oral
Pharmacokinetic data
Protein binding	< 20%
Identifiers
CAS number	107233-08-9 Y
ATC code	N07AX03
PubChem	CID 83898
DrugBank	DB00185
ChemSpider	75707 Y
UNII	K9V0CDQ56E Y
KEGG	D07667 Y
ChEMBL	CHEMBL1201267 N
Chemical data
Formula	C10H17NOS
Mol. mass	489.565 g/mol
SMILES	eMolecules & PubChem
InChI InChI=1S/C10H17NOS/c1-8-12-10(7-13-8)6-11-4-2-9(10)3-5-11/h8-9H,2-7H2,1H3/t8-,10-/m1/s1 Y Key:WUTYZMFRCNBCHQ-PSASIEDQSA-N Y
N (what is this?)  (verify)

Cevimeline (Evoxac) is a parasympathomimetic and muscarinic agonist,^[1] with particular effect on M₃ receptors. It is used in the treatment of dry mouth associated with Sjögren's syndrome.

Mechanism of action [link]

By activating the M₃ receptors of the parasympathetic nervous system, cevimeline stimulates secretion by the salivary glands, thereby alleviating dry mouth.

Side effects [link]

Known side effects include nausea, vomiting, diarrhea, excessive sweating, rash, headache, runny nose, cough, drowsiness, hot flashes, blurred vision, and difficulty sleeping.^[2]

Contraindications include asthma and angle closure glaucoma.^{[citation needed]}

See also [link]

Salagen - a similar parasympathomimetic medication for dry mouth (Xerostomia)

References [link]

External links [link]

• Evoxac website